Merck And Co Inc 's Revenue in the fiscal year 2025 $ 65,011.00 millions
Merck And Co Inc 's Revenue in the fiscal year 2024 $ 64,168.00 millions
Merck And Co Inc 's Revenue in the fiscal year 2023 $ 60,115.00 millions
Merck And Co Inc 's Revenue in the fiscal year 2022 $ 59,283.00 millions
Merck And Co Inc 's Revenue in the fiscal year 2021 $ 48,704.00 millions
MRK Revenue second quarter 2026 Y/Y Growth Comment
Merck and Co Inc reported Revenue growth of 5.07% year on year in the second quarter 2026, to $ 16,607.00 millions, this is lower than Merck And Co Inc 's recent average Revenue growth of 6.52%.
Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 116 other companies have achieved higher Revenue growth. While Merck And Co Inc ' s Revenue increase of 5.07% ranks overall at the positon no. 2235 in the second quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Merck And Co Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
66.84 %
1.65 %
-22.43 %
(Dec. 30, 2009)
MRK's II. Quarter Q/Q Revenue Comment
Merck and Co Inc achieved in the II. Quarter 2026 above company average sequential Revenue growth of 1.97%, to $ 16,607.00 millions, from $16,286.00 millions in the first quarter. MRK is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Major Pharmaceutical Preparations industry 76 other companies have achieved higher Revenue quarter on quarter growth. While Merck And Co Inc 's Revenue growth quarter on quarter, overall rank is 1494.
Merck and Co Inc achieved in the II. Quarter 2026 above company average sequential Revenue growth of 1.97%, to $ 16,607.00 millions, from $16,286.00 millions in the first quarter. MRK is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Major Pharmaceutical Preparations industry 76 other companies have achieved higher Revenue quarter on quarter growth. While Merck And Co Inc 's Revenue growth quarter on quarter, overall rank is 1494.
Merck And Co Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 30 2026)
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending
$ 66,569.00
$ 65,768.00
$ 65,011.00
$ 64,235.00
$ 63,616.00
Y / Y Revenue Growth (TTM)
4.64 %
2.89 %
1.31 %
1.68 %
1.82 %
Year on Year Revenue Growth Overall
Ranking
# 2276
# 1858
# 1530
# 1493
# 1296
Seqeuential Revenue Change (TTM)
1.22 %
1.16 %
1.21 %
0.97 %
-0.48 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2676
# 2491
# 2070
# 2081
# 1914
Cumulative Revenue growth Comment
Although Merck And Co Inc 's Annual Revenue growth year on year were below company's average 6.08% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 4.64% year on year, from 2.89% in Mar 31 2026.
In the Healthcare sector 331 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1858 to 2276.
Although Merck And Co Inc 's Annual Revenue growth year on year were below company's average 6.08% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 4.64% year on year, from 2.89% in Mar 31 2026.
In the Healthcare sector 331 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1858 to 2276.
About Merck And Co Inc Revenue Growth Rates (MRK), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
8.83%